Dual antiplatelet therapy shows promise in South Indian heart disease patients

Heart disease kills more people globally than almost any other condition, and the drugs we use to prevent blood clots in arteries remain imperfect. Aspirin has been the standard treatment for decades—cheap, available, proven to work in many patients. But doctors have long wondered whether adding a second antiplatelet drug, clopidogrel, might offer better protection, especially in populations where genetic differences and distinct patterns of vascular disease might change how these medications behave.

A research team at a tertiary care hospital in South India set out to explore this question in their own patient population. They enrolled 84 adults with either heart disease or stroke over a nine-month observation period. Thirty-one patients took aspirin alone; 53 received both aspirin and clopidogrel together. The researchers tracked what happened: deaths, hospitalizations, and recurrent heart attacks or strokes. They also measured quality of life using standard questionnaires and estimated each patient's risk of bleeding complications using a validated scoring system called HAS-BLED.

The numbers suggested a meaningful difference. Among patients on dual therapy, 15.1 percent experienced a major adverse event by the nine-month mark. In the aspirin-only group, that figure reached 54.8 percent—more than three times higher. At an earlier checkpoint, the gap was similarly stark: 13.2 percent for dual therapy versus 38.7 percent for aspirin alone. The statistical tests indicated these differences were unlikely to be due to chance.

But the researchers were careful about what their own data could actually claim. The study was observational, not randomized—doctors chose which patients got which treatment based on their clinical judgment, not by random assignment. The two groups differed at the start in ways that mattered: their underlying diagnoses varied, as did smoking rates and alcohol consumption. These baseline imbalances meant that some of the benefit attributed to dual therapy might have reflected differences in the patients themselves rather than differences in the drugs. When the team looked at individual outcomes rather than the composite measure, the advantage of dual therapy no longer reached statistical significance.

There was another gap in the evidence. The researchers estimated that two-thirds of their patients carried moderate to high bleeding risk according to the HAS-BLED framework. Yet they did not actually track whether patients experienced bleeding events during the study. This meant they could not weigh the potential harm of adding a second antiplatelet agent against its apparent benefits. They did find that patients on dual therapy reported higher pain and discomfort scores, though physical functioning remained similar between groups.

The authors were explicit about the limits of what they had found. This was exploratory work, hypothesis-generating rather than hypothesis-confirming. The findings described an association—dual therapy appeared linked to fewer adverse events in this South Indian cohort—but they did not establish causation or superiority. Before clinicians in South Asia or elsewhere could confidently recommend dual therapy over aspirin monotherapy, the results would need confirmation in larger, randomized trials with careful attention to both benefits and harms. The distinct genetic architecture and vascular risk profiles of South Asian populations meant that evidence from other regions could not simply be transplanted. The question remained open, and the data pointed toward the next step: rigorous, controlled research that could actually answer it.